Title: Bcl-2 inhibitors reduce steroid-insensitive airway inflammation.
Journal: The Journal of allergy and clinical immunology 20170801
Title: CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia.
Journal: Oncotarget 20170627
Title: Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.
Journal: Cell death and differentiation 20161201
Title: Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling.
Journal: Chemico-biological interactions 20160425
Title: Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Journal: International journal of cancer 20150301
Title: Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway.
Journal: Toxicology and applied pharmacology 20140115
Title: Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.
Journal: Molecular cancer therapeutics 20131001
Title: Inhibition of pluripotent stem cell-derived teratoma formation by small molecules.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20130827
Title: ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Journal: Biochemical pharmacology 20130401
Title: The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737.
Journal: The Journal of biological chemistry 20130308
Title: N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.
Journal: Leukemia 20121001
Title: Effect of dual inhibition of apoptosis and autophagy in prostate cancer.
Journal: The Prostate 20120901
Title: Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
Journal: Cellular signalling 20120901
Title: CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737.
Journal: Experimental hematology 20120901
Title: Acidosis promotes Bcl-2 family-mediated evasion of apoptosis: involvement of acid-sensing G protein-coupled receptor Gpr65 signaling to Mek/Erk.
Journal: The Journal of biological chemistry 20120810
Title: Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
Journal: International journal of molecular medicine 20120801
Title: Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Journal: Cell death & disease 20120801
Title: Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein.
Journal: Bioorganic & medicinal chemistry 20120715
Title: Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
Journal: Journal of medicinal chemistry 20120712
Title: Bax and Bcl-xL exert their regulation on different sites of the ceramide channel.
Journal: The Biochemical journal 20120701
Title: Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak.
Journal: Oncogene 20120628
Title: Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
Journal: Cancer research 20120615
Title: Tax protein-induced expression of antiapoptotic Bfl-1 protein contributes to survival of human T-cell leukemia virus type 1 (HTLV-1)-infected T-cells.
Journal: The Journal of biological chemistry 20120615
Title: Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival.
Journal: Blood 20120614
Title: Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Journal: Blood 20120614
Title: Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
Journal: Journal of medicinal chemistry 20120614
Title: Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120601
Title: Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro.
Journal: Leukemia 20120601
Title: ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
Journal: The Journal of pharmacology and experimental therapeutics 20120601
Title: 2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines.
Journal: Oncogene 20120531
Title: Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function.
Journal: Blood 20120503
Title: Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis.
Journal: Leukemia 20120501
Title: ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Journal: Experimental hematology 20120501
Title: Structure-activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction.
Journal: European journal of medicinal chemistry 20120501
Title: Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.
Journal: Cancer letters 20120428
Title: A defect in cell death of macrophages is a conserved feature of nonobese diabetic mouse.
Journal: Biochemical and biophysical research communications 20120427
Title: Pharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice.
Journal: Cell death and differentiation 20120401
Title: Genetically defining the mechanism of Puma- and Bim-induced apoptosis.
Journal: Cell death and differentiation 20120401
Title: Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.
Journal: Leukemia 20120401
Title: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Journal: Leukemia 20120401
Title: Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad.
Journal: Apoptosis : an international journal on programmed cell death 20120401
Title: N-terminally cleaved Bcl-xL mediates ischemia-induced neuronal death.
Journal: Nature neuroscience 20120401
Title: Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.
Journal: Bioorganic & medicinal chemistry 20120401
Title: Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway.
Journal: Cell death & disease 20120401
Title: Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells.
Journal: Molecular cell 20120330
Title: Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation.
Journal: The Journal of biological chemistry 20120323
Title: Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.
Journal: Molecular cancer research : MCR 20120301
Title: Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
Journal: Cancer 20120215
Title: Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells.
Journal: Pediatric surgery international 20120201
Title: p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737.
Journal: Apoptosis : an international journal on programmed cell death 20120201
Title: Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120201
Title: [The effect of cell killing by ABT-737 synergized with docetaxel in human prostate cancer PC-3 cells].
Journal: Zhonghua wai ke za zhi [Chinese journal of surgery] 20120201
Title: Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120115
Title: Calcium homeostasis in vascular smooth muscle cells is altered in type 2 diabetes by Bcl-2 protein modulation of InsP3R calcium release channels.
Journal: American journal of physiology. Heart and circulatory physiology 20120101
Title: Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737.
Journal: Cancer research 20120101
Title: Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
Journal: Bioorganic & medicinal chemistry letters 20120101
Title: Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
Journal: PloS one 20120101
Title: Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition.
Journal: Leukemia research 20111201
Title: RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines.
Journal: Neuro-oncology 20111201
Title: The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells.
Journal: Molecular cancer therapeutics 20111201
Title: Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20111115
Title: Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia.
Journal: Blood 20111110
Title: miR-193b Regulates Mcl-1 in Melanoma.
Journal: The American journal of pathology 20111101
Title: The two faces of FBW7 in cancer drug resistance.
Journal: BioEssays : news and reviews in molecular, cellular and developmental biology 20111101
Title: Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis.
Journal: Cell death & disease 20111101
Title: ABT-737 is highly effective against molecular subgroups of multiple myeloma.
Journal: Blood 20111006
Title: GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1.
Journal: Cancer letters 20111001
Title: Evaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis.
Journal: Journal of leukocyte biology 20111001
Title: The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Journal: Experimental hematology 20111001
Title: Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.
Journal: Pathology 20111001
Title: Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase.
Journal: Nature cell biology 20111001
Title: An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.
Journal: Blood 20110929
Title: BH3 mimetics activate multiple pro-autophagic pathways.
Journal: Oncogene 20110915
Title: ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110915
Title: Molecular dynamics study of small molecule inhibitors of the Bcl-2 family.
Journal: Proteins 20110901
Title: Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.
Journal: Blood 20110811
Title: Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
Journal: Blood 20110804
Title: Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737.
Journal: Cellular oncology (Dordrecht) 20110801
Title: Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.
Journal: Cancer research 20110801
Title: Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
Journal: The Journal of biological chemistry 20110715
Title: MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.
Journal: Cancer research 20110701
Title: Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1.
Journal: Molecular cancer therapeutics 20110701
Title: The BH3-mimetic ABT-737 inhibits allogeneic immune responses.
Journal: Transplant international : official journal of the European Society for Organ Transplantation 20110701
Title: Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis.
Journal: Cell death & disease 20110701
Title: BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation.
Journal: Blood 20110630
Title: The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.
Journal: Molecular pharmacology 20110601
Title: Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.
Journal: Leukemia & lymphoma 20110601
Title: The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance.
Journal: Cell death & disease 20110601
Title: Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.
Journal: Cancer research 20110515
Title: The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein.
Journal: Biochemical and biophysical research communications 20110506
Title: 3D-QSAR study on a series of Bcl-2 protein inhibitors using comparative molecular field analysis.
Journal: Protein and peptide letters 20110501
Title: BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets.
Journal: The Journal of biological chemistry 20110422
Title: Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110415
Title: Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
Journal: Journal of medicinal chemistry 20110324
Title: Mutation to Bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis.
Journal: The Journal of biological chemistry 20110304
Title: SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.
Journal: Nature 20110303
Title: The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid.
Journal: Cancer chemotherapy and pharmacology 20110301
Title: Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
Journal: Pediatric blood & cancer 20110301
Title: Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1.
Journal: The Journal of clinical investigation 20110301
Title: Apoptosis induces Bcl-XS and cleaved Bcl-XL in chronic lymphocytic leukaemia.
Journal: Biochemical and biophysical research communications 20110218
Title: Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.
Journal: Molecular oncology 20110201
Title: The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.
Journal: Cancer research 20110201
Title: The BH3 mimetic ABT-737 induces cancer cell senescence.
Journal: Cancer research 20110115
Title: Bcl-x(L) blocks a mitochondrial inner membrane channel and prevents Ca2+ overload-mediated cell death.
Journal: PloS one 20110101
Title: Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.
Journal: PloS one 20110101
Title: The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma.
Journal: BMC cancer 20110101
Title: The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
Journal: PloS one 20110101
Title: Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma.
Journal: PloS one 20110101
Title: Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
Journal: PloS one 20110101
Title: MicroRNA-195 promotes apoptosis in mouse podocytes via enhanced caspase activity driven by BCL2 insufficiency.
Journal: American journal of nephrology 20110101
Title: Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Journal: Pediatric blood & cancer 20101201
Title: Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins.
Journal: Molecular cancer therapeutics 20101201
Title: Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.
Journal: Molecular cancer therapeutics 20101201
Title: Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.
Journal: Blood 20101118
Title: Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
Journal: Cancer biology & therapy 20101101
Title: Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737.
Journal: Cancer biology & therapy 20101101
Title: Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Journal: Journal of medicinal chemistry 20101014
Title: The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Journal: Hepatology (Baltimore, Md.) 20101001
Title: Synthesis and biological activities of new di- and trimeric quinoline derivatives.
Journal: Bioorganic & medicinal chemistry 20101001
Title: Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100901
Title: Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100815
Title: The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
Journal: Journal of immunology (Baltimore, Md. : 1950) 20100815
Title: Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin.
Journal: Leukemia 20100801
Title: BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma.
Journal: Molecular cancer research : MCR 20100801
Title: Multiple ligand simultaneous docking: orchestrated dancing of ligands in binding sites of protein.
Journal: Journal of computational chemistry 20100730
Title: Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis.
Journal: Cancer research 20100701
Title: ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.
Journal: Molecular cancer therapeutics 20100701
Title: p53 up-regulated modulator of apoptosis (PUMA) activation contributes to pancreatic beta-cell apoptosis induced by proinflammatory cytokines and endoplasmic reticulum stress.
Journal: The Journal of biological chemistry 20100625
Title: New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.
Journal: The Prostate 20100601
Title: Mitochondrial fragmentation and neuronal cell death in response to the Bcl-2/Bcl-x(L)/Bcl-w antagonist ABT-737.
Journal: Neuropharmacology 20100601
Title: Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA.
Journal: Pigment cell & melanoma research 20100601
Title: ARC synergizes with ABT-737 to induce apoptosis in human cancer cells.
Journal: Molecular cancer therapeutics 20100601
Title: BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists.
Journal: Cell death and differentiation 20100501
Title: Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.
Journal: Blood 20100422
Title: Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.
Journal: Blood 20100408
Title: Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells.
Journal: Leukemia research 20100401
Title: Nucleoside analog ARC targets Mcl-1 to induce apoptosis in leukemia cells.
Journal: Leukemia 20100401
Title: Bcl-2 antagonists and cancer: from the clinic, back to the bench.
Journal: Cell death & disease 20100401
Title: The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
Journal: Molecular pharmacology 20100301
Title: ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.
Journal: Biochemical pharmacology 20100201
Title: Regulation of stress-induced nuclear protein redistribution: a new function of Bax and Bak uncoupled from Bcl-x(L).
Journal: Cell death and differentiation 20100201
Title: Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells.
Journal: Autophagy 20100201
Title: A small molecule-regulated guanine nucleotide exchange factor.
Journal: Journal of the American Chemical Society 20100127
Title: Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.
Journal: Nature 20100107
Title: Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction.
Journal: The Journal of clinical investigation 20100104
Title: Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization.
Journal: PloS one 20100101
Title: Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1.
Journal: Molecular cancer 20100101
Title: ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress.
Journal: Cancer chemotherapy and pharmacology 20091201
Title: [Apoptosis resistance in malignant tumors: novel apoptosis-based therapeutic approaches].
Journal: Der Pathologe 20091201
Title: BH3-only protein bid participates in the Bcl-2 network in healthy liver cells.
Journal: Hepatology (Baltimore, Md.) 20091201
Title: The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
Journal: Leukemia 20091101
Title: Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands.
Journal: The Journal of biological chemistry 20091030
Title: Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
Journal: Journal of medicinal chemistry 20091008
Title: The antiapoptotic protein Bcl-xL negatively regulates the bone-resorbing activity of osteoclasts in mice.
Journal: The Journal of clinical investigation 20091001
Title: Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20091001
Title: Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria.
Journal: Molecular pharmacology 20090901
Title: Bcl-2 modulation to activate apoptosis in prostate cancer.
Journal: Molecular cancer research : MCR 20090901
Title: Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.
Journal: Cancer biology & therapy 20090801
Title: Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
Journal: American journal of respiratory cell and molecular biology 20090701
Title: Different forms of cell death induced by putative BCL2 inhibitors.
Journal: Cell death and differentiation 20090701
Title: Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737.
Journal: Leukemia & lymphoma 20090701
Title: The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity.
Journal: Journal of immunology (Baltimore, Md. : 1950) 20090615
Title: Immunosensitization with a Bcl-2 small molecule inhibitor.
Journal: Cancer immunology, immunotherapy : CII 20090501
Title: ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
Journal: Molecular pharmacology 20090501
Title: Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.
Journal: Nature reviews. Cancer 20090501
Title: Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Journal: Cancer research 20090501
Title: Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
Journal: Blood 20090430
Title: Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
Journal: Blood 20090423
Title: BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Journal: The Journal of investigative dermatology 20090401
Title: Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
Journal: Molecular cancer therapeutics 20090401
Title: Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.
Journal: Cell death and differentiation 20090301
Title: Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma.
Journal: Cancer research 20090301
Title: Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors.
Journal: Blood 20090226
Title: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090215
Title: Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells.
Journal: Blood 20090212
Title: Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.
Journal: Journal of cellular physiology 20090101
Title: RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway.
Journal: PloS one 20090101
Title: Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081215
Title: Mimicking the BH3 domain to kill cancer cells.
Journal: Oncogene 20081201
Title: Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081115
Title: Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
Journal: Journal of medicinal chemistry 20081113
Title: Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
Journal: Oncogene 20081106
Title: Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
Journal: The Journal of clinical investigation 20081103
Title: Anticancer therapy: boosting the bang of Bim.
Journal: The Journal of clinical investigation 20081103
Title: Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.
Journal: Blood 20081015
Title: The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Journal: Blood 20081001
Title: Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.
Journal: Cancer research 20081001
Title: Vitamin D3 induces autophagy of human myeloid leukemia cells.
Journal: The Journal of biological chemistry 20080912
Title: ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
Journal: The Journal of biological chemistry 20080905
Title: Long live the cell death!
Journal: Cell death and differentiation 20080801
Title: Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death.
Journal: Oncogene 20080710
Title: Essential role for Nix in autophagic maturation of erythroid cells.
Journal: Nature 20080710
Title: BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death.
Journal: Cell cycle (Georgetown, Tex.) 20080701
Title: [Progress in small-molecule inhibitors of Bcl-2 family proteins].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20080701
Title: Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?
Journal: Cell death and differentiation 20080601
Title: A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.
Journal: Cell death and differentiation 20080501
Title: Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
Journal: Cancer research 20080501
Title: Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Journal: Journal of the National Cancer Institute 20080416
Title: BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
Journal: Cancer research 20080415
Title: Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
Journal: Cancer research 20080401
Title: Bcl-xL inhibitor ABT-737 reveals a dual role for Bcl-xL in synaptic transmission.
Journal: Journal of neurophysiology 20080301
Title: BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.
Journal: Blood 20080215
Title: ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
Journal: British journal of haematology 20080101
Title: Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Journal: International journal of cancer 20071201
Title: BH3 mimetics to improve cancer therapy; mechanisms and examples.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20071201
Title: The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20071201
Title: Bcl-2-regulated apoptosis: mechanism and therapeutic potential.
Journal: Current opinion in immunology 20071001
Title: Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
Journal: PLoS medicine 20071001
Title: Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
Journal: Blood 20070915
Title: Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Journal: Cell death and differentiation 20070901
Title: Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family.
Journal: Cell death and differentiation 20070901
Title: BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
Journal: Leukemia 20070801
Title: BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.
Journal: Cancer cell 20070801
Title: ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.
Journal: Leukemia 20070701
Title: 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
Journal: Oncogene 20070607
Title: Bcl-2 family proteins are essential for platelet survival.
Journal: Cell death and differentiation 20070501
Title: Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.
Journal: Journal of medicinal chemistry 20070419
Title: A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Journal: Oncogene 20070405
Title: Targeting multiple arms of the apoptotic regulatory machinery.
Journal: Cancer research 20070401
Title: Programmed anuclear cell death delimits platelet life span.
Journal: Cell 20070323
Title: Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction.
Journal: British journal of cancer 20070226
Title: Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Journal: Journal of medicinal chemistry 20070222
Title: Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
Journal: Cancer research 20070201
Title: Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Journal: Cancer research 20070115
Title: The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070115
Title: Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.
Journal: The Journal of clinical investigation 20070102
Title: Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.
Journal: Current topics in medicinal chemistry 20070101
Title: Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
Journal: Cell cycle (Georgetown, Tex.) 20061201
Title: Restoring cancer's death sentence.
Journal: Cancer cell 20061101
Title: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
Journal: Cancer cell 20061101
Title: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
Journal: Cancer cell 20061101
Title: A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
Journal: Cancer research 20060901
Title: Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.
Journal: Cancer cell 20060501
Title: Emerging drugs for chronic lymphocytic leukaemia.
Journal: Expert opinion on emerging drugs 20060301
Title: [New hope for the cancer patient?].
Journal: Pharmazie in unserer Zeit 20060101
Title: Targeting mitochondria emerges as therapeutic strategy.
Journal: Journal of the National Cancer Institute 20051221
Title: Defects of the apoptotic pathway as therapeutic target against cancer.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20051201
Title: BCL-2: found bound and drugged!
Journal: Trends in molecular medicine 20051001
Title: Killing cancer cells by flipping the Bcl-2/Bax switch.
Journal: Cancer cell 20050701
Title: An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
Journal: Nature 20050602
Title: Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer.
Journal: Hematology. American Society of Hematology. Education Program 20050101
Title: Subversion of the Bcl-2 life/death switch in cancer development and therapy.
Journal: Cold Spring Harbor symposia on quantitative biology 20050101
Title: A matter of life and death.
Journal: Cancer cell 20020201
Title: An informatics approach identifying markers of chemosensitivity in human cancer cell lines.
Journal: Cancer research 20001101
Title: Konopleva M, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006 Nov;10(5):375-88.
Title: Ahamed Saleem, et al. Effect of dual inhibition of apoptosis and autophagy in prostate cancer. Prostate. 2012 Sep 1;72(12):1374-81.
Title: Clerc P, et al. Polster BM.Rapid Detection of an ABT-737-Sensitive Primed for Death State in Cells Using Microplate-Based Respirometry.PLoS One. 2012;7(8):e42487. Epub 2012 Aug 3.
